Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Farzana Perwad, MD

Title(s)Associate Professor, Pediatrics
SchoolSchool of Medicine
Phone415-476-2423
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    My research focus is to understand the molecular mechanisms of regulation of phosphorus and vitamin D metabolism in the setting of chronic kidney disease.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cil O, Perwad F. a-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases. Pediatrics. 2020 Apr 03. PMID: 32245805.
      View in: PubMed
    2. Balani S, Perwad F. Fibroblast growth factor 23 and phosphate homeostasis. Curr Opin Nephrol Hypertens. 2019 09; 28(5):465-473. PMID: 31335449.
      View in: PubMed
    3. Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biol Blood Marrow Transplant. 2019 10; 25(10):2031-2039. PMID: 31199983.
      View in: PubMed
    4. Perwad F, Portale AA. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD. Clin J Am Soc Nephrol. 2019 07 05; 14(7):1097-1099. PMID: 31171590.
      View in: PubMed
    5. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int. 2019 Sep; 105(3):271-284. PMID: 31165191.
      View in: PubMed
    6. Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 06 15; 393(10189):2416-2427. PMID: 31104833.
      View in: PubMed
    7. Egli-Spichtig D, Imenez Silva PH, Glaudemans B, Gehring N, Bettoni C, Zhang MYH, Pastor-Arroyo EM, Schönenberger D, Rajski M, Hoogewijs D, Knauf F, Misselwitz B, Frey-Wagner I, Rogler G, Ackermann D, Ponte B, Pruijm M, Leichtle A, Fiedler GM, Bochud M, Ballotta V, Hofmann S, Perwad F, Föller M, Lang F, Wenger RH, Frew I, Wagner CA. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney Int. 2019 Oct; 96(4):890-905. PMID: 31301888.
      View in: PubMed
    8. Roberts MS, Burbelo PD, Egli-Spichtig D, Perwad F, Romero CJ, Ichikawa S, Farrow E, Econs MJ, Guthrie LC, Collins MT, Gafni RI. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J Clin Invest. 2018 12 03; 128(12):5368-5373. PMID: 30226830.
      View in: PubMed
    9. Egli-Spichtig D, Zhang MYH, Perwad F. Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury. Front Physiol. 2018; 9:1494. PMID: 30405444.
      View in: PubMed
    10. Keung L, Perwad F. Vitamin D and kidney disease. Bone Rep. 2018 Dec; 9:93-100. PMID: 30591927.
      View in: PubMed
    11. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 08; 33(8):1383-1393. PMID: 29947083.
      View in: PubMed
    12. Cil O, Perwad F. Monogenic Causes of Proteinuria in Children. Front Med (Lausanne). 2018; 5:55. PMID: 29594119.
      View in: PubMed
    13. Mary Scott Ramnitz, Peter Burbelo, Daniela Egli-Spichtig, Farzana Perwad, Christopher Romero, Shoji Ichikawa, Emily Farrow, Michael Econs, Lori Guthrie, Rachel I. Gafni, Michael T. Collins. Autoimmune hyperphosphatemic tumoral calcinosis. Bone Abstracts. 2017 Jul 11.
      View in: Publisher Site
    14. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016 11 07; 11(11):1989-1998. PMID: 27561289.
      View in: PubMed
    15. Portale AA, Zhang MY, David V, Martin A, Jiao Y, Gu W, Perwad F. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. PLoS One. 2015; 10(11):e0142924. PMID: 26588476.
      View in: PubMed
    16. Farzana Perwad, Anthony Portale. Phosphate Homeostasis and Metabolic Bone Disease. The Physiological Basis of Metabolic Bone Disease. 2014 May 27; 137-166.
      View in: Publisher Site
    17. Chanakul A, Zhang MY, Louw A, Armbrecht HJ, Miller WL, Portale AA, Perwad F. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One. 2013; 8(9):e72816. PMID: 24019880.
      View in: PubMed
    18. Zhang MY, Ranch D, Pereira RC, Armbrecht HJ, Portale AA, Perwad F. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology. 2012 Apr; 153(4):1806-16. PMID: 22334725.
      View in: PubMed
    19. Anthony A. Portale, Farzana Perwad, Walter L. Miller. Chapter 25 Rickets Due to Hereditary Abnormalities of Vitamin D Synthesis or Action. Pediatric Bone. 2012 Jan 1; 679-698.
      View in: Publisher Site
    20. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol. 2011 Dec 05; 347(1-2):17-24. PMID: 21914460.
      View in: PubMed
    21. Ranch D, Zhang MY, Portale AA, Perwad F. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res. 2011 Aug; 26(8):1883-90. PMID: 21472778.
      View in: PubMed
    22. Anthony A. Portale, Farzana Perwad. Calcium and Phosphorus. Pediatric Nephrology. 2009 Jan 1; 231-265.
      View in: Publisher Site
    23. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007 Nov; 293(5):F1577-83. PMID: 17699549.
      View in: PubMed
    24. Kim CJ, Kaplan LE, Perwad F, Huang N, Sharma A, Choi Y, Miller WL, Portale AA. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab. 2007 Aug; 92(8):3177-82. PMID: 17488797.
      View in: PubMed
    25. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005 Dec; 146(12):5358-64. PMID: 16123154.
      View in: PubMed